125 related articles for article (PubMed ID: 32112230)
1. Interobserver agreement of [
Derwael C; Lavergne O; Lovinfosse P; Nechifor V; Salvé M; Waltregny D; Hustinx R; Withofs N
EJNMMI Res; 2020 Feb; 10(1):15. PubMed ID: 32112230
[TBL] [Abstract][Full Text] [Related]
2. Interobserver and intraobserver agreement on prostate-specific membrane antigen PET/CT images according to the miTNM and PSMA-RADS criteria.
Demirci E; Akyel R; Caner B; Alan-Selçuk N; Güven-Meşe Ş; Ocak M; Kabasakal L
Nucl Med Commun; 2020 Aug; 41(8):759-767. PubMed ID: 32453205
[TBL] [Abstract][Full Text] [Related]
3.
Basha MAA; Hamed MAG; Hussein O; El-Diasty T; Abdelkhalek YI; Hussein YO; Alasamer AF; Mohamed HAE; Deen DSE; Tantawy EF; Metwally MI; Zaitoun MMA; Aly SA; Altohamy JI; Mohamed AEM; Afifi AHM; Harb O
Abdom Radiol (NY); 2019 Jul; 44(7):2545-2556. PubMed ID: 30963182
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 3 Interpretation Criteria for
Toriihara A; Nobashi T; Baratto L; Duan H; Moradi F; Park S; Hatami N; Aparici CM; Davidzon G; Iagaru A
J Nucl Med; 2020 Apr; 61(4):533-539. PubMed ID: 31562226
[TBL] [Abstract][Full Text] [Related]
5. Interreader agreement in evaluation of 68Ga-PSMA PET/CT at the time of initial staging: comparison of the three evaluation criteria in the pretreatment risk groups.
Karahan Şen NP; Aksu A; Bozkurt O; Tuna EB; Çapa Kaya G
Nucl Med Commun; 2022 Jan; 43(1):86-91. PubMed ID: 34559761
[TBL] [Abstract][Full Text] [Related]
6. Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on
Werner RA; Bundschuh RA; Bundschuh L; Javadi MS; Leal JP; Higuchi T; Pienta KJ; Buck AK; Pomper MG; Gorin MA; Lapa C; Rowe SP
J Nucl Med; 2018 Dec; 59(12):1857-1864. PubMed ID: 30190304
[TBL] [Abstract][Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
8. High Interobserver Agreement on PSMA PET/CT Even in the Absence of Clinical Data.
Bundschuh RA; Lütje S; Bundschuh L; Lapa C; Higuchi T; Hartrampf PE; Gorin MA; Kosmala A; Buck AK; Pomper MG; Rowe SP; Essler M; Sheikh GT; Werner RA
Clin Nucl Med; 2023 Mar; 48(3):207-212. PubMed ID: 36723879
[TBL] [Abstract][Full Text] [Related]
9. The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.0.
Kuten J; Dekalo S; Mintz I; Yossepowitch O; Mano R; Even-Sapir E
EJNMMI Res; 2021 Jan; 11(1):3. PubMed ID: 33409930
[TBL] [Abstract][Full Text] [Related]
10.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
11. A VISION Substudy of Reader Agreement on
Kuo PH; Yoo DC; Avery R; Seltzer M; Calais J; Nagarajah J; Weber WA; Fendler WP; Hofman MS; Krause BJ; Brackman M; Kpamegan E; Ghebremariam S; Benson T; Catafau AM; Kendi AT
J Nucl Med; 2023 Aug; 64(8):1259-1265. PubMed ID: 37230533
[TBL] [Abstract][Full Text] [Related]
12. Can
Liu Y; Niu S; Luan X; Zhang X; Liu J; Zhang J; Wang R; Xu B; Zhang X
Transl Androl Urol; 2023 Jan; 12(1):83-89. PubMed ID: 36760865
[TBL] [Abstract][Full Text] [Related]
13. Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET/CT scans in prostate cancer patients.
Grawe F; Blom F; Winkelmann M; Burgard C; Schmid-Tannwald C; Unterrainer LM; Sheikh GT; Pfitzinger PL; Kazmierczak P; Cyran CC; Ricke J; Stief CG; Bartenstein P; Ruebenthaler J; Fabritius MP; Geyer T
Eur Radiol; 2024 Feb; 34(2):1157-1166. PubMed ID: 37624414
[TBL] [Abstract][Full Text] [Related]
14. Ga-PSMA PET/CT Staging of Newly Diagnosed Intermediate- and High-Risk Prostate Cancer.
Kuten J; Mabjeesh NJ; Lerman H; Levine C; Barnes S; Even-Sapir E
Isr Med Assoc J; 2019 Feb; 21(2):100-104. PubMed ID: 30772960
[TBL] [Abstract][Full Text] [Related]
15. Gallium-68-prostate-specific membrane antigen (
van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L
BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
[TBL] [Abstract][Full Text] [Related]
16. aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in
Nickols N; Anand A; Johnsson K; Brynolfsson J; Borreli P; Parikh N; Juarez J; Jafari L; Eiber M; Rettig M
J Nucl Med; 2022 Feb; 63(2):233-239. PubMed ID: 34049980
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of [
Koehler D; Sauer M; Karimzadeh A; Apostolova I; Klutmann S; Adam G; Knipper S; Maurer T; Berliner C
EJNMMI Res; 2022 Oct; 12(1):66. PubMed ID: 36210356
[TBL] [Abstract][Full Text] [Related]
18. PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy.
Wang H; Amiel T; Würnschimmel C; Langbein T; Steiger K; Rauscher I; Horn T; Maurer T; Weber W; Wester HJ; Knorr K; Eiber M
EJNMMI Res; 2021 Aug; 11(1):76. PubMed ID: 34417907
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Performance of [
Paymani Z; Rohringer T; Vali R; Loidl W; Alemohammad N; Geinitz H; Langsteger W; Beheshti M
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32708097
[TBL] [Abstract][Full Text] [Related]
20. Correlation between Intraprostatic PSMA Uptake and MRI PI-RADS of [
Zhao J; Mangarova DB; Brangsch J; Kader A; Hamm B; Brenner W; Makowski MR
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33255971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
